ANUHPHR vs DRAGARWQ: Stock Comparison
DR. AGARWAL'S EYE HOSP L is the larger company by market capitalisation. ANUH PHARMA shows a lower P/E, a higher dividend yield and faster revenue growth, while DR. AGARWAL'S EYE HOSP L shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ANUHPHR leads 5; DRAGARWQ leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ANUHPHR | DRAGARWQ |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | ANUHPHR | DRAGARWQ |
|---|---|---|
| Live Price | ₹95.5 | ₹5,277.5 |
| Day Change | 7.04% | 0.15% |
| Volume | 2.46 L | 559 |
| 52-Week High | ₹99.5 | ₹6,059.7 |
| 52-Week Low | ₹67 | ₹4,600 |
| Distance from 52W High | -4.02% | -12.91% |
Valuation
| Metric | ANUHPHR | DRAGARWQ |
|---|---|---|
| Market Cap | ₹966 Cr | ₹2,548 Cr |
| P/E Ratio | 20.86x | 33.43x |
| P/B Ratio | 2.62x | 7.36x |
| EPS | ₹3.53 | ₹48.38 |
| Book Value | ₹35.14 | ₹716.56 |
| Dividend Yield | 1.66% | 0.2% |
Growth
| Metric | ANUHPHR | DRAGARWQ |
|---|---|---|
| Revenue Growth (TTM YoY) | 2% | 0% |
| EPS Growth (TTM YoY) | -6% | 0% |
| Qtr Sales Growth | -74.88% | -69.64% |
| Qtr Profit Growth | -72.17% | -66.65% |
Profitability & Leverage
| Metric | ANUHPHR | DRAGARWQ |
|---|---|---|
| ROE | 11.65% | 20.24% |
| ROCE | 11.96% | 18.74% |
| Net Margin | 5.32% | 14.89% |
| Operating Margin | 7.09% | 22.4% |
| Debt to Equity | 0x | 0.24x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ANUHPHR | DRAGARWQ |
|---|---|---|
| Promoter Holding | 71.78% | 72.67% |
| FII Holding | 0.01%▼ 0.04 pp | 2.24%▲ 0.04 pp |
| DII Holding | 0% | 2.05%▼ 0.07 pp |
| Public Holding | 28.19%▲ 0.03 pp | 23.04%▲ 0.04 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANUH PHARMA and DR. AGARWAL'S EYE HOSP L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.